United Therapeutics Corporation
UTHR
$322.94
$15.705.11%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 21.35% | 23.46% | 22.71% | 44.24% | 35.40% |
| Total Depreciation and Amortization | 36.28% | 26.19% | 16.06% | 5.37% | 3.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 216.67% | 10.32% | -1.20% | -68.70% | -77.10% |
| Change in Net Operating Assets | 38.45% | -57.29% | 22.08% | -126.13% | 30.74% |
| Cash from Operations | 35.70% | 18.95% | 27.39% | 10.25% | 21.87% |
| Capital Expenditure | -6.99% | -24.74% | -17.19% | -36.43% | -65.99% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 265.93% | 219.79% | 230.45% | 209.18% | 40.54% |
| Cash from Investing | 157.98% | 161.25% | 152.49% | 135.16% | 11.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -300.00% | -- | -- | -- | 87.50% |
| Issuance of Common Stock | 53.06% | -7.20% | -25.61% | -43.30% | 10.92% |
| Repurchase of Common Stock | -7,234.78% | -7,286.86% | -7,231.88% | -7,231.16% | -21.05% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | 0.00% | 0.00% | 0.00% | 64.00% |
| Cash from Financing | -10,444.54% | -1,033.21% | -984.54% | -935.93% | -115.78% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 98.58% | 216.68% | 5.99% | -74.87% | 271.23% |
